Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone
Citation
Price , D , Henley , W , Delfini Cançado , J E , Fabbri , L M , Kerstjens , H AM , Papi , A , Roche , N , Şen , E , Singh , D , Vogelmeier , C , Barille , S , Nudo , E , Carter , V , Skinner , D , Vella , R & Georges , G 2022 , ' Interclass difference in pneumonia risk in COPD patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone ' , International journal of chronic obstructive pulmonary disease , vol. 2022 , no. 17 , pp. 355—370 . https://doi.org/10.2147/COPD.S342357
Rights
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.